High rates of tuberculosis in patients accessing HAART in rural South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 4, 2014, Pages 438-446

  Naidoo, Kogieleum ^a   Karim, Quarraisha Abdool ^a,b   Bhushan, Ambika ^a,c   Naidoo, Kasavan ^a   Yende Zuma, Nonhlanhla ^a   McHunu, Patricia K ^a   Frohlich, Janet ^a   Karim, Farina ^a   Upfold, Michele ^a   Kocheleff, Paul ^a   Karim, Salim S Abdool ^a,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Department of Medicine   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Africa; HAART; HIV; KwaZulu Natal; South Africa; TB; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; CHECKLIST; CLINICAL ASSESSMENT; CONFERENCE PAPER; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HEALTH CARE ACCESS; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; INCIDENCE; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIODIAGNOSIS; RETROSPECTIVE STUDY; RURAL AREA; SOUTH AFRICA; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; SYMPTOM ASSESSMENT; THORAX RADIOGRAPHY; TUBERCULOSIS;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RADIOGRAPHY, THORACIC; RETROSPECTIVE STUDIES; RURAL POPULATION; SOUTH AFRICA; SPUTUM; TUBERCULOSIS; YOUNG ADULT;

EID: 84898719615     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000060     Document Type: Conference Paper

References (47)

1. WHO. Global Tuberculosis Control-Epidemiology, Strategy, Financing. WHO Report 2009. Geneva, Switzerland. 2009
2. W.H.O. Global Tuberculosis Control 2011. Geneva, Switzerland. Available at: Http://www.who.int/tb/publications/global-report/2011/gtbr11- full.pdf. Accessed January 30, 2013
3. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, et al. HIV infection and tuberculosis in South Africa: An urgent need to escalate the public health response. Lancet. 2009;374:921-933
4. Barnighausen T, Tanser F, Gqwede Z, et al. High HIV incidence in a community with high HIV prevalence in rural South Africa: Findings from a prospective population-based study. AIDS. 2008;22:139-144
5. HST. Reported cases of TB (all types) (per 100 000). 2010. Available at: Http://www.hst.org.za/healthstats/16/data. Accessed December 2010
6. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: A cohort study. Lancet. 2002;359:2059-2064
7. Girardi E, Sabin CA, d́Arminio Monforte A, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005;41:1772-1782
8. Miranda A, Morgan M, Jamal L, et al. Impact of antiretroviral therapy on the incidence of tuberculosis: The Brazilian experience, 1995-2001. PloS One. 2007;2:e826
9. Santoro-Lopes G, de Pinho AM, Harrison LH, et al. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis. 2002;34:543-546
10. HIV-CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis. 2012;54:1364-1372
11. Lawn SD, Harries AD, Williams BG, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it Int J Tuberc Lung Dis. 2011;15:571-581
12. Girardi E, Antonucci G, Vanacore P, et al. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J. 2004;24:11-17
13. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362: 697-706
14. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492-1501
15. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481
16. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-1491
17. D.o.H. National antiretroviral treatment guideline. National Department of health South Africa. 2004. Available at: Http://southafrica.usembassy. gov/media/2004-doh-art-guidelines.pdf. Accessed January 30, 2014
18. D.o.H. The South African Antiretroviral Treatment Guidelines. 2010. Available at: Http://www.uj.ac.za/EN/CorporateServices/ioha/Documentation/ Documents/ART%20Guideline.pdf
19. DoH, South, Africa. National tuberculosis management guidelines 2009. Available at: Http://familymedicine.ukzn.ac.za/Libraries/Guidelines-Protocols/ TB-Guidelines-2009.sflb.ashx
20. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516-523
21. Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med. 2010;182:1080-1085
22. Worodria W, Massinga-Loembe M, Mayanja-Kizza H, et al. Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIVinfected patients starting ART. Clin Dev Immunol. 2011;2011:758350
23. McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: Drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196 (suppl 1):S63-S75
24. Martinson NA, Moultrie H, van Niekerk R, et al. HAART and risk of tuberculosis in HIV-infected South African children: A multi-site retrospective cohort. Int J Tuberc Lung Dis. 2009;13:862-867
25. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21:713-719
26. Bonnet MM, Pinoges LL, Varaine FF, et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS. 2006;20:1275-1279
27. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: Long term incidence and risk factors in a South African cohort. AIDS. 2005;19:2109-2116
28. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1- infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet. 2006;367: 817-824
29. Castelnuovo B, Manabe YC, Kiragga A, et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis. 2009;49:965-972
30. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908
31. Chi BH, Giganti M, Mulenga PL, et al. CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2009;52:125-131
32. Egger S, Petoumenos K, Kamarulzaman A, et al. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr. 2009;50:513-520
33. Gonzalez OY, Adams G, Teeter LD, et al. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis. 2003;7:1178-1185
34. Moore DM, Harris R, Lima V, et al. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr. 2009;52:357-363
35. Nakanjako D, Kiragga A, Ibrahim F, et al. Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: Frequency and clinical significance. AIDS Res Ther. 2008;5:23
36. Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: A collaborative analysis of prospective studies. AIDS. 2008;22:2291-2302
37. Lawn SD, Wood R. Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clin Infect Dis. 2005;41:1783-1786
38. Dembele M, Saleri N, Carvalho AC, et al. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. Int J Tuberc Lung Dis. 2010;14:318-323
39. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: Impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605-1612
40. Hermans SM, Kiragga AN, Schaefer P, et al. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PloS One. 2010;5:e10527
41. Corbett EL, Bandason T, Cheung YB, et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med. 2007;4:e22
42. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis. 2005;40:1500-1507
43. Cohen T, Murray M, Wallengren K, et al. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: A postmortem study. PLoS Med. 2010;7: E1000296
44. Martinson NA, Karstaedt A, Venter WD, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: An autopsy study. AIDS. 2007;21:2043-2050
45. Gupta A, Wood R, Kaplan R, et al. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PloS One. 2013;8:e55824
46. Manabe YC, Breen R, Perti T, et al. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: A disease spectrum after initiation of antiretroviral therapy. J Infect Dis. 2009;199: 437-444
47. Leone S, Nicastri E, Giglio S, et al. Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: A systematic review. Int J Infect Dis. 2010;14:e283-291